Caribou Biosciences, Inc. Stock-Based Compensation
Caribou Biosciences, Inc. (CRBU) reported Stock-Based Compensation of $4.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.48M, a 20.84% decline year-over-year.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.36M, a 39.28% decline year-over-year.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.74M, a 29.99% decline year-over-year.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.93M, a 27.97% decline year-over-year.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $12.68M, a 24.10% decline from fiscal 2024.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $16.71M, a 21.50% increase from fiscal 2023.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $13.75M, a 17.36% increase from fiscal 2022.
- Caribou Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $11.72M, a 239.69% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.83M 10-Q · filed 2026-08-13 | $7.57M derived: sum of 3 quarters · filed 2026-08-13 | $10.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.36M 10-Q · filed 2026-05-07 | $5.09M derived: sum of 2 quarters · filed 2026-05-07 | $8.03M derived: sum of 3 quarters · filed 2026-05-07 | $11.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.67M derived: sum of 2 quarters · filed 2026-03-05 | $8.80M derived: sum of 3 quarters · filed 2026-08-13 | $12.68M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.06M derived: sum of 2 quarters · filed 2026-08-13 | $9.94M 10-Q · filed 2025-11-12 | $13.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.01M 10-Q · filed 2026-08-13 | $10.92M derived: sum of 3 quarters · filed 2026-08-13 | $14.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.88M 10-Q · filed 2026-05-07 | $7.79M derived: sum of 2 quarters · filed 2026-05-07 | $11.86M derived: sum of 3 quarters · filed 2026-05-07 | $16.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.98M derived: sum of 2 quarters · filed 2026-03-05 | $12.72M derived: sum of 3 quarters · filed 2026-03-05 | $16.71M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.81M derived: sum of 2 quarters · filed 2025-11-12 | $12.79M 10-Q · filed 2025-11-12 | $16.35M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $8.73M 10-Q · filed 2025-08-12 | $12.28M derived: sum of 3 quarters · filed 2025-08-12 | $15.76M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.99M 10-Q · filed 2025-05-08 | $7.54M derived: sum of 2 quarters · filed 2025-05-08 | $11.02M derived: sum of 3 quarters · filed 2025-05-08 | $14.61M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $7.03M derived: sum of 2 quarters · filed 2025-03-10 | $10.62M derived: sum of 3 quarters · filed 2025-03-10 | $13.75M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.06M derived: sum of 2 quarters · filed 2024-11-06 | $10.19M 10-Q · filed 2024-11-06 | $13.29M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.72M 10-Q · filed 2024-08-06 | $9.82M derived: sum of 3 quarters · filed 2024-08-06 | $12.49M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $3.13M 10-Q · filed 2024-05-07 | $6.23M derived: sum of 2 quarters · filed 2024-05-07 | $8.90M derived: sum of 3 quarters · filed 2024-05-07 | $11.82M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $5.77M derived: sum of 2 quarters · filed 2024-03-11 | $8.69M derived: sum of 3 quarters · filed 2024-03-11 | $11.72M 10-K · filed 2024-03-11 |
| 2022-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.59M derived: sum of 2 quarters · filed 2023-11-07 | $8.62M 10-Q · filed 2023-11-07 | $10.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.94M 10-Q · filed 2023-08-08 | $7.52M derived: sum of 3 quarters · filed 2023-08-08 | $8.46M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $3.02M 10-Q · filed 2023-05-09 | $4.60M derived: sum of 2 quarters · filed 2023-05-09 | $5.54M derived: sum of 3 quarters · filed 2023-05-09 | $6.13M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.51M derived: sum of 2 quarters · filed 2023-03-09 | $3.11M derived: sum of 3 quarters · filed 2023-03-09 | $3.45M 10-K · filed 2023-03-09 |
| 2021-09-30 | $935.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.53M derived: sum of 2 quarters · filed 2022-11-08 | $1.87M 10-Q · filed 2022-11-08 | $2.10M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $593.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $936.00K 10-Q · filed 2022-08-09 | $1.17M derived: sum of 3 quarters · filed 2022-08-09 | $1.42M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $343.00K 10-Q · filed 2022-05-09 | $574.00K derived: sum of 2 quarters · filed 2022-05-09 | $822.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $479.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.00M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $771.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $523.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $1.23M 10-K · filed 2022-03-21 | |||
| 2018-12-31 | $700.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |